More news: Research
Agency / Source: Royal DSM N.V.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Actamax™ Submits IDE to FDA for Pivotal Study on Novel Sprayable Adhesion Barrier Device - Actamax Surgical Materials, LLC announced that it has submitted an Investigational Device Exemption (IDE) to the US Food and Drug Administration (FDA) to study the Actamax™ Adhesion Barrier - Actamax.com
Actamax™ Submits IDE to FDA for Pivotal Study on Novel Sprayable Adhesion Barrier Device

 

PRZOOM - /newswire/ - Exton, PA, United States, 2017/02/21 - Actamax Surgical Materials, LLC announced that it has submitted an Investigational Device Exemption (IDE) to the US Food and Drug Administration (FDA) to study the Actamax™ Adhesion Barrier - Actamax.com. Euronext: DSM KON

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Actamax Surgical Materials, LLC, a wholly owned subsidiary of DSM Biomedical focusing on the development and commercialization of resorbable, biocompatible surgical medical devices that reduce the burden of post-operative complications, today announced that it has submitted an Investigational Device Exemption (IDE) to the US Food and Drug Administration (FDA) to study the Actamax™ Adhesion Barrier in a prospective, randomized controlled trial in gynecological laparoscopic surgery. In pre-submission meetings, Actamax worked constructively with the FDA to discuss questions and concerns and has used FDA’s feedback to determine path forward for its IDE application.

"This IDE submission marks an important next step in advancing our Actamax Adhesion Barrier on the path to regulatory approval and commercialization," said Marc Hendriks, Ph.D., President of Actamax. "Previously obtained results from both the First-in-Human trial and the ensuing 12 months, long-term follow-up on the use of this adhesion barrier product are very promising. We believe that the data we are submitting to the FDA supports the safety and efficacy of the Actamax Adhesion Barrier. The proposed pivotal study in a larger population will help clarify the product’s place in the area of abdominopelvic surgery, where post-surgical adhesions are considered the most frequent complication.”

Surgery, trauma, infection and chronic inflammation (such as endometriosis) can elicit the formation of adhesions as part of the body’s normal healing response. Adhesions are excessive scar tissue that forms between adjacent internal tissues. A significant number of patients with adhesions develop complications ranging from discomfort, chronic pain and infertility (in women), to life-threatening consequences such as small bowel obstruction.

Previously, the safety, efficacy, and ease of use of the Actamax Adhesion Barrier was demonstrated in a 78-patient, multi-center clinical study in women undergoing a variety of gynecological surgeries. In the ensuing 12 month clinical follow-up of 47 study patients, there was evidence suggestive of improved long-term outcomes, including a lower recurrence rate of pre-study symptoms, and a higher probability of pregnancy in patients with whom the Actamax Adhesion Barrier was used.

About Actamax

Actamax Surgical Materials, LLC (actamax.com) is a DSM company. Actamax was founded in 2011 and is developing a new generation of resorbable, biocompatible surgical devices dedicated to improve patient outcomes and lives.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Royal DSM N.V.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


Actamax™ Submits IDE to FDA for Pivotal Study on Novel Sprayable Adhesion Barrier Device

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Actamax Surgical Material | DSM Biomedical
Contact: Marc Hendriks - Actamax.com 
510-809-4388 marc.hendriks[.]dsm.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Royal DSM N.V. securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Royal DSM N.V. / Company Profile


Read Research Most Recent Related Press Releases:

ZAGENO Applauded by Frost & Sullivan for Simplifying the Supply Chain for Life Science Research with its e-Commerce Platform
Bruker Launches NMR-based Molecular Phenomics Clinical Research Tool for ‘Long COVID’ Multi-Organ Risk Assessment
Otto Schott Research Award Recognizes Achievements in Glass Science
Swave, A New Imec and VUB, Spin-off, Raises €7M to Deliver Truly Realistic AR/VR Experiences to Applications Like The Metaverse
Frost & Sullivan Awards EBSCO Information Services for Delivering Innovative Solutions to Access Medical Research Information for Healthcare Providers
International Conference on Machine Learning & Data Mining to Debut July 16-21, 2022 in New York USA
Elanco and Royal DSM Announce Strategic Alliance in U.S. for Bovaer® A Revolutionary, Methane-Reducing Feed Additive for Cattle
Canopy Biosciences Launches the First of a Series of Targeted Assay Kits for ChipCytometry
Safran Teams Up with the University of Limoges, CNRS and the National Research Agency to Inaugurate the Joint X-SELANS Lab
DSM’s Global Head Office to Move to Maastricht, The Netherlands

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  RightITnow, Inc.

Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2022 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today